According to our new market research study on “Fluorescent Immunoassay Market to 2028 – Global Analysis and Forecast – by Product Type, Application, and End User,” the market is expected to grow from US$ 2,578.66 million in 2021 to US$ 3,778.78 million by 2028. The market is estimated to grow at a CAGR of 5.6% from 2021 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the global fluorescent immunoassay market growth.

Factors such as growing prevalence of chronic diseases and increasing demand for cell therapies are expected to boost the growth of the global fluorescent immunoassay market. However, the market is likely to get impacted by the disadvantages of fluorescent immunoassays during the forecast period. Several immunoassay techniques do not require the use of a labeled reactant. Some depend upon the precipitation line that forms gel support when any form of protein antigen comes into contact with its specific antibody. In contrast, other manual and automated methods for endpoint detection depend on the increase in light scatter generated. Despite their extensive and rapidly increasing use, unlabeled methods are limited to analyzing proteins and other large molecules present at relatively high concentrations. Only with high concentrations are the resulting antigen: antibody complexes large enough to produce a precipitate line or scatter to form bright. Additional disadvantages include the need for relatively large amounts of monospecific antisera, problems with very turbid or hemolyzed samples, and the possibility of erroneous results in the presence of antigen excess due to the prozone phenomenon.

Fluorescence immunoassay is a sensitive technique that is used in the measurement of many compounds, including drugs, hormones, and proteins; in the identification of antibodies; and in the quantification of antigens such as viral particles and, potentially, bacteria. The fluorescence detection system includes higher sensitivity detection of the analyte, simplified reagents, and simpler assay designs.

According to the National Center for Chronic Disease Prevention, in 2018, little over a quarter of adults in the US (27.2%) had several chronic illnesses. Multiple chronic illnesses were more common in women, non-Hispanic white people, older adults, Medicaid-eligible individuals aged 18–64, dual-eligible adults (Medicare and Medicaid), and adults in rural areas. Chronic diseases are among the most common and expensive health problems in the US.

North America dominated the fluorescence immunoassay analyzers market due to the high prevalence of infectious and chronic diseases, improved technology, laboratory automation, and a favorable reimbursement landscape. According to the National Center for Chronic Disease Prevention and Health Promotion, at least one chronic condition affects six out of ten Americans. Chronic diseases such as heart disease and stroke, cancer, and diabetes are the main causes of death and disability in the US, as well as a major driver of healthcare expenses.

Get Sample Copy with Complete TOC and Figures & Graphs @ 

@ https://www.theinsightpartners.com/sample/TIPRE00011093/

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com